Loading quotes...
Forecast
The analysts' average price target is €77.63 (+19.89%). The median is €74.21 (+14.61%).
| Buy |
13 |
| Hold |
10 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Stifel Financial hits 52-week low at $67.95 despite strong quarterly results
Stifel Financial’s stock fell to a 52-week low of $67.95 and is currently trading near $67.89, giving it a market capitalization of about $10.45 billion. The shares have lost roughly 17.8% over six months and 16.2% year-to-date. At the same time, the company reported strong Q1 results with operating earnings per share of $1.45, revenue up 18% to $1.48 billion, assets under management of $579.7 billion and a dividend of $0.34 per share; analysts see valuation metrics suggesting undervaluation. » More on de.investing.com
Stifel Financial announces quarterly dividend of $0.34
Stifel Financial declared a cash dividend of $0.34 per common share, payable on June 15, 2026 to shareholders of record on June 1, 2026. The board also confirmed quarterly dividends for three series of preferred stock (Series B, C and D) with respective distributions of approximately $0.390625, $0.3828125 and $0.28125 per depositary share. The dividend reflects the company’s nine years of rising payouts; the current yield is 1.73 percent. Investor note: the preferred dividends cover the period from March 16 to June 15, 2026. » More on de.investing.com
Stifel exceeds Q1 2026 expectations on earnings and revenue, stock slightly under pressure
Stifel reports adjusted EPS of $1.45 for Q1 2026 (expectation $1.37) and revenue of $1.48bn (expectation $1.44bn), driven by strong investment banking fees. Despite the positive results, the stock fell 0.38% in pre-market trading to $81.96. Management highlights company-wide AI initiatives and venture lending as growth drivers and reaffirms a positive outlook with EPS guidance between $1.46 and $2.09 and expected Q2 revenue of about $1.47bn. Risks remain from market volatility, geopolitical tensions and interest-rate uncertainty. » More on de.investing.com
Acumen Pharmaceuticals presents Sabirnetug strategy at Stifel forum
Acumen Pharmaceuticals provided a strategic overview of Sabirnetug, which targets toxic, soluble Aβ oligomers in Alzheimer’s. The phase 2 ALTITUDE‑AD study with 542 recruits was completed in 10 months; results are expected at the end of 2026 and are seen as key to validating the Aβ oligomer hypothesis. The company is collaborating with JCR Pharmaceuticals to improve brain uptake using IZCARGO and aims to file an IND for the EBD program by mid‑2027. Acumen remains open to partnerships for phase 3 development, depending on the ALTITUDE‑AD results; the subcutaneous formulation will continue to be evaluated. » More on de.investing.com
Stifel Financial beats Q4-2025 forecasts, announces stock split and dividend increase
Stifel Financial reported Q4 2025 earnings per share of $2.63 (expectation $2.51) and revenue of $1.56 billion (expectation $1.5 billion). Management announced a 3-for-2 stock split and an 11% dividend increase. For 2026, net revenue is expected between $6.0 billion and $6.35 billion; 2025 was a record year with $5.5 billion. Despite the positive results, the stock moved little in premarket trading, and the company continues to show strong margins and a high return on tangible equity. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 1.44B | 4.66% |
| Gross profit | 1.25B | 4.15% |
| Net profit | 206.71M | 14.77% |
| EBITDA | 280.37M | 7.11% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.65B |
Number of shares | 149.24M |
52-week high/low | €81.80 - €59.55 |
Dividend yield | 1.93% |
Dividends TTM | €1.27 |
Next dividend | €0.31 |
Beta | 1.02 |
P/E ratio | 10.25 |
PEG ratio | 0.70 |
P/B ratio | 1.78 |
P/S ratio | 1.58 |
Company profile
Stifel Financial Corp., a financial services and bank holding company, provides retail and institutional wealth management, and investment banking services to individual investors, corporations, municipalities, and institutions in the United States, the United Kingdom, the rest of Europe, and Canada. It operates in three segments: Global Wealth Management, Institutional Group, and Other. The company provides private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading and research, and municipal finance services; investment banking services, such as mergers and acquisitions, public offerings, and private placements; and retail and commercial banking services comprising personal and commercial lending programs, as well as deposit accounts. It also participates in and manages underwritings for corporate and public finance; and offers financial advisory and securities brokerage services. The company was founded in 1890 and is headquartered in St. Louis, Missouri.
| Name | Stifel Financial Co. |
| CEO | Ronald James Kruszewski |
| Headquarters | Saint Louis,
mo USA |
| Website | |
| Sector | Financials |
| Industry | Financial Services |
| IPO | 07/19/1983 |
| Employees | 8,900 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | SF |
Frankfurt | 2SI.F |
Düsseldorf | 2SI.DU |